Mayne Pharma Group Limited (ASX:MYX)
Australia · Delayed Price · Currency is AUD 2.915
+0.075 (2.64%)
Feb 11, 2026, 10:59 AM AEST
Mayne Pharma Group Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 408.1 | 388.4 | 183.59 | 157.15 | 400.78 | |
Revenue Growth (YoY) | 5.07% | 111.56% | 16.82% | -60.79% | -12.30% |
Cost of Revenue | 160.82 | 169.62 | 100.1 | 85.58 | 218.8 |
Gross Profit | 247.27 | 218.78 | 83.49 | 71.57 | 181.98 |
Selling, General & Admin | 251.4 | 276.38 | 251.19 | 181.89 | 172.69 |
Research & Development | 17.91 | 20.24 | 15.73 | 12.21 | 21.69 |
Operating Expenses | 269.3 | 296.61 | 266.92 | 194.1 | 194.38 |
Operating Income | -22.03 | -77.84 | -183.43 | -122.53 | -12.4 |
Interest Expense | -39.8 | -35 | -10.42 | -10.7 | -12.02 |
Interest & Investment Income | 4.91 | 7.07 | 6.72 | 0.46 | 0.69 |
Currency Exchange Gain (Loss) | 2.13 | -0.53 | -9.52 | 0.85 | -1.92 |
Other Non Operating Income (Expenses) | 1.72 | 1.11 | -13.98 | -16 | -19.73 |
EBT Excluding Unusual Items | -53.07 | -105.2 | -210.63 | -147.91 | -45.38 |
Merger & Restructuring Charges | -1.63 | -0.89 | -12.15 | -5.01 | -9.5 |
Gain (Loss) on Sale of Assets | - | - | - | 3.74 | - |
Asset Writedown | - | - | -69.18 | -68.29 | -229.32 |
Legal Settlements | -12.05 | -1.33 | -5.09 | -2.89 | -2.12 |
Other Unusual Items | -16.56 | -82.67 | 23.9 | 74.77 | 22.43 |
Pretax Income | -83.3 | -190.09 | -269.7 | -145.59 | -263.89 |
Income Tax Expense | 6.78 | -21.47 | 47.75 | 74.5 | -54.81 |
Earnings From Continuing Operations | -90.07 | -168.62 | -317.44 | -220.09 | -209.08 |
Earnings From Discontinued Operations | -3.77 | -5.61 | 434.6 | -71.81 | - |
Net Income to Company | -93.84 | -174.23 | 117.16 | -291.89 | -209.08 |
Minority Interest in Earnings | - | - | 0.09 | 10.61 | 0.66 |
Net Income | -93.84 | -174.23 | 117.25 | -281.29 | -208.42 |
Net Income to Common | -93.84 | -174.23 | 117.25 | -281.29 | -208.42 |
Shares Outstanding (Basic) | 79 | 80 | 82 | 82 | 79 |
Shares Outstanding (Diluted) | 79 | 80 | 82 | 82 | 79 |
Shares Change (YoY) | -0.60% | -3.11% | -0.15% | 4.74% | 2.75% |
EPS (Basic) | -1.19 | -2.19 | 1.43 | -3.42 | -2.65 |
EPS (Diluted) | -1.19 | -2.19 | 1.43 | -3.42 | -2.65 |
Free Cash Flow | 5.19 | -23.25 | -51.05 | -17.22 | 41.77 |
Free Cash Flow Per Share | 0.07 | -0.29 | -0.62 | -0.21 | 0.53 |
Gross Margin | 60.59% | 56.33% | 45.48% | 45.54% | 45.41% |
Operating Margin | -5.40% | -20.04% | -99.92% | -77.97% | -3.09% |
Profit Margin | -22.99% | -44.86% | 63.87% | -179.00% | -52.00% |
Free Cash Flow Margin | 1.27% | -5.99% | -27.81% | -10.96% | 10.42% |
EBITDA | 42.08 | -14.5 | -116.53 | -46.34 | 50.04 |
EBITDA Margin | 10.31% | -3.73% | -63.48% | -29.49% | 12.49% |
D&A For EBITDA | 64.11 | 63.33 | 66.9 | 76.19 | 62.45 |
EBIT | -22.03 | -77.84 | -183.43 | -122.53 | -12.4 |
EBIT Margin | -5.40% | -20.04% | -99.92% | -77.97% | -3.09% |
Revenue as Reported | 408.1 | 388.4 | 183.59 | 157.15 | 400.78 |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.